Oxcarbazepine (Trileptal, Novartis) was approved as adjunctive therapy to treat partial seizures in children aged 2 years or older with epilepsy.
Oxcarbazepine (Trileptal, Novartis) was approved as adjunctive therapy to treat partial seizures in children aged 2 years or older with epilepsy.
Abatacept (Orencia, Bristol-Myers Squibb) was approved to reduce the signs and symptoms of moderately to severely active rheumatoid arthritis in adult patients who have had an inadequate response to 1 or more disease-modifying antirheumatic drugs (DMARDs).
FDA approved divalproex extended-release tablets (Depakote ER, Abbott) for the treatment of acute manic or mixed episodes associated with bipolar disorder, with or without psychotic features.
Iowa Expands PBM Legislation to Address Concerns of Independent Pharmacies
May 16th 2025A new law in Iowa, if signed by the governor, will mandate 100% pass-through of rebates, increased financial transparency, and a minimal payment for pharmacies. Critics say it will be the most costly mandate in the state’s history.
Read More
Is Arkansas’ New PBM Law the Right Path Forward for Reform? No One Knows Yet
May 9th 2025It could improve access to community pharmacies and lower prices. Or it will limit access to critical drugs and impact payers’ ability to contract for a broad range of services. Industry leaders are unsure about the impact of Arkansas’ law banning PBMs from owning pharmacies.
Read More